Roundtable Discussion: Building Effective Public–Private Partnerships to Accelerate Biomarker Discovery & Clinical Trial Readiness in Rare Kidney Disease
- How can academia, industry, and patient groups effectively collaborate to generate and share high-quality datasets while maintaining competitive advantages?
- What are the biggest barriers to building and scaling shared research platforms (e.g., data standardization, access, governance), and how can these be overcome?
- How can stakeholders align on the validation and use of biomarkers to support clinical trial design and regulatory acceptance?